SML1586

Oritavancin diphosphate

≥97% (HPLC)

• 别名: LY333328 diphosphate, (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3"-[(4′-chloro[l,1′-biphenyl]-4-yl)methyl]vancomycin diphosphate, LY-333328
• 经验公式（希尔记法）: C₈₆H₉₇Cl₃N₁₀O₂₆ · 2H₃PO₄
• CAS号: 192564-14-0
• 分子量: 1989.09
• UNSPSC代码: 12352200
• NACRES: NA.77

属性

• 质量水平: 100
• 方案: ≥97% (HPLC)
• 表单: powder
• 颜色: white to beige
• 溶解性: H₂O: 10 mg/mL, clear
• 运输: wet ice
• 储存温度: −20°C
• SMILES字符串: [P](=O)(O)(O)O.[P](=O)(O)(O)O.Clc1ccc(cc1)c2ccc(cc2)CN[C@@]3([C@H]([C@@H](O[C@H](C3)O[C@H]4[C@@H](O[C@@H]([C@H]([C@@H]4O)O)CO)Oc5c6cc7cc5Oc8c(cc(cc8)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]7C(=O)N[C@@H]9c%10cc(c(cc%10)O)c%11c(cc(cc%11O)O)[C@H](NC(=O)[C@@H](NC9
• InChI: 1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1
• InChI key: PWTROOMOPLCZHB-BHYQHFGMSA-N

说明

生化/生理作用

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days.

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens.

注意

category 1 skin sensitizer

安全信息

• 象形图: GHS07
• 警示用语：: Warning
• 危险声明: H317
• 预防措施声明: P261 - P272 - P280 - P302 + P352 - P333 + P313 - P362 + P364
• 危险分类: Skin Sens. 1A
• 储存分类代码: 11 - Combustible Solids
• WGK: WGK 3
• 闪点(°F): Not applicable
• 闪点(°C): Not applicable